These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Strategies for preventing respiratory syncytial virus. Forbes M Am J Health Syst Pharm; 2008 Dec; 65(23 Suppl 8):S13-9. PubMed ID: 19020197 [TBL] [Abstract][Full Text] [Related]
24. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Langley GF; Anderson LJ Pediatr Infect Dis J; 2011 Jun; 30(6):510-7. PubMed ID: 21487331 [TBL] [Abstract][Full Text] [Related]
25. Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus infection? The case in favour. Resch B; Resch E; Müller W Paediatr Respir Rev; 2013 Jun; 14(2):130-6. PubMed ID: 23375547 [TBL] [Abstract][Full Text] [Related]
26. Prevention of respiratory syncytial virus infection among Puerto Rican infants. Winchester L; García L; García I; Concepción CB P R Health Sci J; 2002 Sep; 21(3):191-3. PubMed ID: 12243108 [TBL] [Abstract][Full Text] [Related]
31. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710 [TBL] [Abstract][Full Text] [Related]
32. Infection by the respiratory syncytial virus in infants and young children at high risk. Bonnet D; Schmaltz AA; Feltes TF Cardiol Young; 2005 Jun; 15(3):256-65. PubMed ID: 15865827 [TBL] [Abstract][Full Text] [Related]
33. High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention. Manzoni P; Paes B; Resch B; Carbonell-Estrany X; Bont L Early Hum Dev; 2012 May; 88 Suppl 2():S34-41. PubMed ID: 22633511 [TBL] [Abstract][Full Text] [Related]
34. Prophylaxis with palivizumab against respiratory syncytial virus infection in infants with congenital heart disease--who should receive it? Sunnegårdh J Acta Paediatr; 2006 Apr; 95(4):388-90. PubMed ID: 16720482 [TBL] [Abstract][Full Text] [Related]
35. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants. Singleton R; Dooley L; Bruden D; Raelson S; Butler JC Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511 [TBL] [Abstract][Full Text] [Related]
36. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada. Paes B; Steele S; Janes M; Pinelli J Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698 [TBL] [Abstract][Full Text] [Related]
37. Respiratory syncytial virus disease: update on treatment and prevention. Krilov LR Expert Rev Anti Infect Ther; 2011 Jan; 9(1):27-32. PubMed ID: 21171875 [TBL] [Abstract][Full Text] [Related]
38. Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody. Huang K; Wu H Microbiol Spectr; 2014 Aug; 2(4):AID-0014-2014. PubMed ID: 26104207 [TBL] [Abstract][Full Text] [Related]
40. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings. Marchetti A; Lau H; Magar R; Wang L; Devercelli G Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]